167 related articles for article (PubMed ID: 31360909)
1. Targeting WDR5: A WINning Anti-Cancer Strategy?
Aho ER; Weissmiller AM; Fesik SW; Tansey WP
Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
[TBL] [Abstract][Full Text] [Related]
2. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
3. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
Lu K; Tao H; Si X; Chen Q
Front Oncol; 2018; 8():502. PubMed ID: 30488017
[TBL] [Abstract][Full Text] [Related]
4. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
[TBL] [Abstract][Full Text] [Related]
5. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
6. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
7. Fragment screening for a protein-protein interaction inhibitor to WDR5.
Dennis ML; Morrow BJ; Dolezal O; Cuzzupe AN; Stupple AE; Newman J; Bentley J; Hattarki M; Nuttall SD; Foitzik RC; Street IP; Stupple PA; Monahan BJ; Peat TS
Struct Dyn; 2019 Nov; 6(6):064701. PubMed ID: 31768400
[TBL] [Abstract][Full Text] [Related]
8. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik SW; Liu Q; Tansey WP
bioRxiv; 2024 Jan; ():. PubMed ID: 37546802
[TBL] [Abstract][Full Text] [Related]
9. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
Song JJ; Kingston RE
J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.
Florian AC; Woodley CM; Wang J; Grieb BC; Slota MJ; Guerrazzi K; Hsu CY; Matlock BK; Flaherty DK; Lorey SL; Fesik SW; Howard GC; Liu Q; Weissmiller AM; Tansey WP
NAR Cancer; 2022 Mar; 4(1):zcac007. PubMed ID: 35252869
[TBL] [Abstract][Full Text] [Related]
13. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.
Weissmiller AM; Fesik SW; Tansey WP
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202281
[TBL] [Abstract][Full Text] [Related]
14. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets.
Liu L; Guo X; Wang Y; Li G; Yu Y; Song Y; Zeng C; Ding Z; Qiu Y; Yan F; Zhang YX; Zhao C; Zhang Y; Dou Y; Atadja P; Li E; Wang H
Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166600. PubMed ID: 36402263
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
16. Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
Shinsky SA; Cosgrove MS
J Biol Chem; 2015 Oct; 290(43):25819-33. PubMed ID: 26324722
[TBL] [Abstract][Full Text] [Related]
17. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
18. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
19. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
